ArticleScientific reports2025
Impact of microbial biotransformation on Zygophyllum decumbens delile through comparative metabolic insights and evaluation of antihyperglycemic and antimicrobial activities.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pharmacognostic Characterization, Phytochemical Profiling, and In Vitro Biological Evaluation ofInternational journal of molecular sciences · 2026Article
- Microbial biotransformation of Syzygium australe modifies metabolomic profile assessed with multivariate analysis and molecular networking: In vitro and computational studies.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Zygophyllum is known to be used traditionally in the management of several medical conditions, including diabetes, infections, and hypertension. This study aims to monitor the effect of microbial biotransformation on both antihyperglycemic and antimicrobial activities of Zygophyllum decumbens Delile using Aspergillus niger. The metabolic profile before and after biotransformation of the ethyl acetate extract was compared using HPLC-ESI-TOF-MS/MS. Pancreatic lipase, α-amylase, and α-glucosidase in vitro inhibition assays and agar diffusion method were used to evaluate the antihyperglycemic and antimicrobial activities, respectively. Eighty-six metabolites, mainly flavonoids and phenolic acids, with a few miscellaneous metabolites, were tentatively identified in both tested extracts. A 36% potentiation in antihyperglycemic activity was observed following microbial biotransformation. Regarding antimicrobial activity, the minimum inhibitory concentration (MIC) against both E. coli and P. aeruginosa decreased from 0.62 to 0.31 mg/ml, representing a nearly 50% reduction. It was noticed that microbial biotransformation altered 27 of the identified metabolites, which may contribute to the enhanced biological activities detected. The study depicts the first report of metabolic profiles and biological differences of Z. decumbens before and after biotransformation. It also validates the traditional use of Z. decumbens for hyperglycemia and its potential as a natural antimicrobial source.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.